Most of the averages were up 3% or so last week. We were down .1%. Our “OB’s” fell with the exception of Lotus which killed the week.
AVSO, SUPG, EXTR, and LTUS.ob are our favorites.
The DOW was up 3% last week, NASDAQ was up 3.8% and the S+P 500 was up 2.7%. The Russell 3000 and the Wilshire 5000 were both up about 2.8%.
For the year so far, we are up 5.9%. The DOW is up 5.6%, NASDAQ is up 3.4%, S+P 500 is up 4.5%, Russell 3000 up 4.7% and the Wilshire is up 4.5%.
Last week we went 11 stocks up and 7 down. Since inception we are now 51 stocks up and 12 down for a 81% winning percentage (80% is our target win %).
Since our beginning, we have closed out the following positions:
2006-ONXS +11% (Buyout offer)
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2009-HSTM +67% (continued good earnings)
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-CAW EVEN (excluding 2.5 years of dividends)
The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).
For the 45 stocks that we closed out since 2006 (41 were winners) the average net gain was 33%.
Rosetta Stone Inc. (NYSE-RST)-Recommended 3/3/2011)
Closed down $.06 at $13.13
Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Closed down $.05 at $.97
Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Closed up $.20 at $6.45
Skellig Capital Management filed a 13D/A in March pushing CCUR to use their excess cash to do a share buy back. They used examples in the filing of $6.60 and $6.90 a share. They also bought a few more shares of CCUR. Their ownership is up to 5.86%.
SuperGen Inc. (NASDAQ-SUPG)-Recommended 10/4/2010)
Valuation $4.89 (was $4.37, $3.48)
Closed up $.28 at $2.85
Upgraded to BUY by The Street.com recently.
Performance Technolgy (PTIX-Recommended 3/30/2010)
Valuation $3.87-(was $5.03, $5.98, $7.13)
Closed up $.13 at $2.01
Earnings due out March 30th after the market close.
Last earnings out in November. Not good. Sales were down 20% from last year to $6.3 million, and they lost $2.9 million or $.26 per share as they “invested” in sales and marketing. This, plus a bunch of new product announcements will hopefully boost sales and get some attention. Cash per share fell to $2.09, and our valuation fell to $3.87 as cash, sales and margins fell. Still trading below cash value, but that cash is dwindling.
Down 26% HOLD–close to a sell.
Extreme Networks (EXTR-Recommended 3/22/2010)
Valuation-$7.36 (was $7.23, $7.31, $6.82, $6.81)
Closed up $.18 at $3.51
CFO resigned in March. Always makes stockholders jittery, but they also got a new CEO in October last year, so it is not unusual for a CFO to go, shortly after a new CEO comes in. They hired an interim CFO last week while they look for a permanent one.
Earnings out in February. Sales up 7% to $85 million and they made $.10 per share ($.06 if you exclude a favorable litigation settlement) versus a loss last year of $.02 per share. Cash per share rose $.08 to 1.55 and our valuation rose to $7.36. Next quarter guidance was $82-$85 million in sales and earnings of $.05-$.08 per share before a $.04/$.05 write off off some assets.
EXTR entered a settlement agreement with Ramius (Ramius owns 6.4% of EXTR). Declassify the Board, add a Ramius Director and the Ramius Director must be on any committee that reviews “strategic alternatives”. Pushing to sell EXTR obviously.
Still a cheap stock.
Up 16% HOLD
Broadvision (BVSN-Recommended 3/16/2010)
Valuation $22.95-(was $22.31, $21.77, $23.37, $27.15)
$13.87 per share in cash.
Closed up $.33 at $14.48.
Earnings out in January. Revenue was $5.1 million and they made $.01 per share. Cash per share fell a tad to $13.60. Our valuation inched up to $22.95.
Up 7%. HOLD
Ninetowns Internet Technology (NINE-Recommended 1/25/2010)
Valuation-$3.54 (Was $3.54, $3.19)
$2.88 per share in cash
Closed up $.04 at $1.40.
Earning out in October. Sales were $5.67 million for the first 6 months of 2010 and they lost $1 million. Cash rose to $2.88 per share and our valuation stayed at $3.54. Only doing about $10 million a year in sales, but still trading way below (50%) cash value.
Down 9%. BUY
Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Valuation $5.73-(Was $4.38, $4.44, $5.15)
Closed up $.05 at $1.98.
Earnings out in November. Not bad. Cash rose to $2.33 per share and they made $.08 per share. Our valuation jumped to $5.73. Not bad at all. New game coming out in Korea this quarter (War of Gods), although Ragnarok 2 is delayed until at least Q2 2011.
Up 18%. HOLD
AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Closed up $.03 at $1.79.
Earnings out last week. Revenues about $10 million for the quarter and $27.7 for the year. They only lost $2.7 for the quarter and lost $20.5 for the year. Cash was $33.9 million before counting about $14 million of cash received in the current quarter for royalty payments, their Japan deal and sale of stock.
AEZS announced a new partnership for perifosine in Japan. They got $8 million upfront and up to another $60 million in the future. Plus AEZS gets to sell the compound to the company and gets double digit royalties. Not a bad deal.
Riding the tail of Kerx and perifosine, new orphan drug apporval from the FDA and a lot of investor interest in their pipeline of cancer products.
Speculative for sure.
Up 26% HOLD
Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000,and was $10.65 before double up), Valuation –$10.00
Closed down $.02 at $4.44.
Hmmm, CFO and 2 other officers got “change of control” agreements in March. Hope they actually mean something!
SPNC announced earnings in February. Nothing to write home about. Sales decreased 1% to $29.3 million. At least they were able to earn a profit of $.02 a share-even after their million dollar charge for EG. I think the only way we are going to make money on this one is if they are sold. Otherwise they just can’t perform and I think the stock will go nowhere.
Good news. Geisemheimer is off the Board! Now just a consultant through June.
13D filed in November 2010. Paragon Assoc. disclosed a 2 million share (6%) ownership purchased at $5.16 per share. Maybe we have a catalyst finally to push management to do something (like sell this dog).
The company has $33 million in cash ($.99 per share), no debt and is growing about 5% a year. Teetering on a SELL here. Management is just terrible.
Down 22%. HOLD.
Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $15.04 (was $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.55 at $12.08
Constellation continues to sell a few thousand shares here and there. Interesting move. Not sure if it is meant to goad MEDW management into doing something like selling the company to Constellation or someone else. The dollars involved in this sales is peanuts. It has been 9 months since they hired their investment bankers, so it is about time for something to happen.
Earnings out in February. Good again. Sales up 22% to $13.2 million and they made $.21 per share versus $.10 last year. Our valuation rose to $15.04–the highest ever.
MEDW re-engaged William Blair to look at “strategic alternatives”. Got to have an I Banker to sell your company.
Constellation now owns 21.8%. When is the take-over offer??
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 91%. HOLD
Vertro. (VTRO (was-MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $14.23 (was $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed up $.03 at $3.53.
Earnings in March. As predicted they did $9.6 million in revenue and made $.11 a share from continuing operations. Our valuation fell to $14.37 and cash per share was $.88.
Down 57%. HOLD
Angeion Corporation. (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
NEW Valuation $13.60 (was $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed up $.05 at $4.80
Earnings out in March. Not bad we thought. Sales up 7% to $7.1 million and they cut their weak quarter loss from $.20 a share to an adjusted profit of $.02 a share (excluding a severance charge for their ex-CEO). Our valuation fell to $13.60, but again this is their seasonally weak quarter, so we are not upset about it.
Up 26% BUY
OB-abies (Bulletin Board Listed Stocks)
As proven by OPTIO, patience is necessary with these stocks, especially in this Market.
ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.39 (was $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $.58 down $.17.
Earnings out in March. Sales down 2% to $5.238 million, operating income was $254,000 and they made $.02 per share. Our valuation jumped back up to $5.39 on higher than expected margins.
Wake up management–you have a great little company here worth 7X what it is selling for.
Now down 64%. BUY. Still a Huge valuation gap here.
Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.40 (was $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.60, down $.05.
Earnings out in February. Sales were $21.7 million and they made $.02 a share. Our valuation jumped back up to $2.40 a share. Trading at 28% of our valuation. Cheap.
RWWI announced a $5.6 million deal in January. Maybe new management will get the word out on Rand and at least get us over $1.
Down 24%. BUY.
CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $.71 (Was $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.07, closed at $.06.
CTI announced in January that it paid off it’s bank debt with a replacement loan from Fairford-its largest shareholder. Hmmm, not a positive for sure. We still think this is worth a lot more in a sale than it is trading at. Have to keep an eye on this.
Earnings out in November. Sales were down only 6% from $3.6 million last year to $3.3 million, and they lost about $700,000. Their VOIP business continues to drain the company. Sales were a whopping $170,000 and it lost $600,000 excluding depreciation. Our valuation fell a bit to $.71.
At a $3 million market cap, this is stupidly cheap. Their itellectual property is probably worth 10 times this price. They need to liquify this value somehow.
They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.
Still an “undercover” company and stock.
Down 74%. HOLD
Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$4.84 (Was $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $1.52, up $.17
This is the Rodney Dangerfield of stocks. No respect whatsoever. Now trading at less than 2X this years earnings! Ghost stories of ALL Chinese reverse merger companies being shams continue to spook stockholders. We don’t think LTUS is one of them.
Looks like the Mongolian land story has shifted again. Now they intend to keep some of the land and build a distribution facility on it and sell the rest for $50-$80 million. No matter to us, either number is more than their entire market cap right now, and TTM earnings are $.78 per share.
LTUS announced in February that they are expanding their Beijing factory by adding 2 more floors for a total of 11 floors, and that it is still expected to be completed by the end of this June. When the building is complete, they expect to have invested a total of $48 million ($36 million already spent) and that based on current market values, the building will be worth over $100 million. This plus the Mongolian land are worth 3 times the current market cap of LTUS. Oh yeah, then there is the $.80 in annual earnings. Think this is a buy?
The stock split 2 for 1 in December. All of our numbers have been adjusted to reflect this split.
They have $40 million invested in the Mongolian land. If they can just break even, they will solve their perceived liquidity problem and they have 2/3’s of their market cap in cash.
Earnings out in November. Sales up 28% and they made $6.7 million or $.24 per share. 9 month earnings are now $18 million or $.66 per share.
We are trading at just more than 2 times earnings and the company is growing-not contracting. China stocks are out of favor for sure.
They are projecting sales of $74 million and about $.80 of earnings. We expect they will beat these numbers. We bought 50,000 more shares in August personally, another 13,000 in October and another 5,000 in December and another 5,000 in January. Their new Bejing buiding is about 65% complete, and they extended their operating contract for another 20 years.
Down 10%. BUY